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OBJECTIVES This study assessed the predictive value of preprocedural C-reactive protein (CRP) levels on
six-month clinical and angiographic outcome in patients undergoing coronary stent implan-
tation.
BACKGROUND Recent data indicate that low-grade inflammation as detected by elevated CRP serum levels
predicts the risk of recurrent coronary events.
METHODS We prospectively investigated the predictive value of preprocedural CRP-levels on restenosis
and six-month clinical outcome in 276 patients after coronary stent implantation. The
primary combined end point was death due to cardiac causes, myocardial infarction related to
the target vessel and repeat intervention of the stented vessel.
RESULTS Grouping patients into tertiles according to preprocedural CRP-levels revealed that, despite
identical angiographic and clinical characteristics at baseline and after stent implantation, a
primary end point event occurred in 24 (26%) patients of the lowest tertile, in 42 (45.6%) of
the middle tertile and in 38 (41.3%) of the highest CRP tertile, p 5 0.01. On multivariate
analysis, tertiles of CRP levels were independently associated with a higher risk of adverse
coronary events (relative risk 5 2.0 [1.1 to 3.5], tertile I vs. II and III, p 5 0.01) in addition
to the minimal lumen diameter after stent (p 5 0.04). In addition, restenosis rates were
significantly higher in the two upper tertiles compared with CRP levels in the lowest tertile
(45.5% vs. 38.3% vs. 18.5%, respectively, p 5 0.002).
CONCLUSIONS Low-grade inflammation as evidenced by elevated preprocedural serum CRP-levels is an
independent predictor of adverse outcome after coronary stent implantation, suggesting that
a systemically detectable inflammatory activity is associated with proliferative responses
within successfully implanted stents. (J Am Coll Cardiol 2001;37:839–46) © 2001 by the
American College of Cardiology
Atherosclerosis is believed to be a chronic inflammatory
disease of the vessel wall (1). Recent data indicate that
low-grade inflammation as detected by elevated C-reactive
protein (CRP) serum levels predicts the risk of recurrent
coronary events not only in patients with myocardial infarc-
tion (MI) (2,3), stable or unstable angina (4,5) but also in
apparently healthy men (6). These observations suggest that
an individual’s reactivity to inflammatory stimuli plays an
important pathophysiologic role in coronary disease pro-
gression (7,8).
Coronary angioplasty (9) or coronary stent implantation
(10) has been shown to elicit an inflammatory response by
itself. In addition, preprocedural CRP levels appear to be a
powerful predictor of both early and late outcome in
patients undergoing conventional balloon angioplasty (11),
suggesting that preprocedural activation of inflammatory
cells may play a role in the modulation of vessel wall
response to the injury induced by balloon angioplasty.
Stent implantation provides a useful model to assess the
role of inflammation for atherosclerotic disease progression
that is primarily determined by neointimal hyperplasia and
not affected by the chronic shrinking process after conven-
tional balloon angioplasty (12). In addition, stent implan-
tation may modify the biological response of a dilated lesion
by providing a more homogeneous lesion geometry com-
pared with balloon dilation.
Therefore, we prospectively investigated the predictive
value of preprocedural CRP-levels on six-month angio-
graphic and clinical outcome in 276 consecutive patients
undergoing coronary stent implantation.
METHODS
Study population. The study population consisted of 276
patients undergoing coronary stent implantation for objec-
tive evidence of ischemia in patients with angina. Indica-
tions for stenting were: coronary dissection after percutane-
ous transluminal coronary angioplasty (PTCA), suboptimal
results ($30% residual stenosis) after PTCA, lesions in
venous bypass grafts and restenotic lesions. In addition, all
patients undergoing percutaneous coronary intervention for
acute MI were treated by stent implantation. All patients
with a stent successfully inserted in the target lesion were
included in the analysis except for those undergoing stent
implantation during cardiogenic shock or as a bridge to
emergency aortocoronary bypass surgery. Patients with in-
tercurrent inflammatory conditions, local hematoma or
malignancies were excluded. At the time of stenting, all
patients were scheduled for a six-month follow-up angio-
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gram, regardless of symptomatic status. All patients gave
informed consent, and the study was approved by our
institutional ethics committee.
Laboratory analysis. In all patients, serum was collected
immediately before the initial percutaneous coronary inter-
vention after insertion of the arterial sheath for measuring
CRP levels with a commercially available kit (Turbidimetric
test, Boehringer Mannheim, Germany). The measuring
range is 0.3 to 24 mg/dl, with intraassay variation coeffi-
cients ranging from 0.6% to 1.3% and interassay variations
from 1.3% to 6% at different levels of CRP.
Stent implantation procedure. Stent implantation was
performed as previously described (13). In brief, all patients
were on chronic aspirin (100 mg/day) therapy or received
500 mg of aspirin intravenously before the procedure.
Fifteen thousand units of heparin was given after insertion
of the arterial sheath, and if necessary, a repeat bolus of
5,000 U was administered to maintain the activated clotting
time .250 s. Intracoronary glycerol trinitrate (0.2 to
0.3 mg) was given at the start of the procedure, before the
final angiogram and before follow-up angiography. High-
pressure balloon catheters were used for stent implantation
with inflation pressures .10 atm. If necessary, multiple
stents were used for complete coverage of the lesion.
Quantitative coronary angiography. Quantitative mea-
surements were assessed by fully computerized quantitative
angiography (CMS, Medis, Nuenen, Netherlands) (14).
Minimal luminal diameter (MLD), reference diameter and
percent diameter stenosis were measured in identical views
before PTCA, immediately after stent insertion and at
follow-up. Lesions were classified according to the modified
American College of Cardiology/American Heart Associa-
tion criteria (15). Analyses were performed per patient (only
one randomly selected lesion per subject). Stent restenosis
was defined as a dichotomous outcome ($50% diameter
stenosis within the stent or stents at follow-up). Acute gain
was defined as the difference between MLD after stent
implantation and the MLD before PTCA. Late loss was
defined as the difference between the MLD after stent
insertion and the MLD at follow-up, and net gain was
defined as the difference between acute gain and late loss.
Postprocedure medication protocol. Ticlopidine 250 mg
to 500 mg per day or Clopidogrel 75 mg/day (n 5 15) was
given for four weeks and aspirin 100 mg/day indefinitely.
Glycoprotein IIb/IIIa inhibitors were administered in 15
patients (5.3%).
Definition of events and follow-up. The primary com-
bined end point was death due to cardiac causes, MI related
to the target vessel and repeat intervention of the stented
vessel (PTCA or aortocoronary bypass surgery). The diag-
nosis of MI was based on typical symptoms and electrocar-
diographic changes plus an increase in creatine kinase $
twice the upper limit of normal with a concomitant rise in
the MB isoenzyme or a positive troponin T test. Blood
samples were routinely drawn 24 h after the procedure in all
patients to detect the occurrence of myocardial necrosis
regardless of symptoms.
Thirty-day clinical follow-up and six-month follow-up
was available in all 276 patients on an outpatient basis. The
cumulative incidence of the primary combined end point,
including death due to cardiac causes, MI related to the
target vessel or repeat intervention of the stented vessel were
assessed by Kaplan-Meier survival curves. Follow-up coro-
nary angiograms to evaluate angiographic stent restenosis
rates were performed in 229 of 267 (85.7%) patients eligible
for planned reangiography between four and six months
after stent placement. Patients who had no-control angiog-
raphy were contacted to obtain clinical follow-up. Target
vessel revascularization (TVR) was defined as repeat inter-
vention of restenotic lesions, which included the target site
of the stent implantation or proximal and distal in the same
major coronary artery. Target vessel revascularization was
driven by the presence of ischemia indicated either by the
recurrence of typical symptoms of angina or a positive
exercise stress test.
Data and statistical analysis. Data are expressed as per-
centages for discrete variables and as mean 6 standard
deviation for continuous variables. C-reactive protein values
were divided into tertiles and compared by Kruskal-Wallis
test or by analysis of variance for multiple comparisons
within all three groups. Categorical variables between two
groups were compared by means of the chi-square test or
Fisher exact test.
Continuous variables were tested for normal distribution
with the Kolmogorov-Smirnov test and compared by means
of Student t test. In case of nonnormal distribution, non-
parametric methods were used (Mann-Whitney U test).
Univariate and stepwise multivariate analysis was performed
using the logistic regression model on SPSS version 8.0,
SPSS Inc. All potential risk factors for stent restenosis were
included. Chi-square analysis or logistic regression was used
to estimate relative risk (RR) and 95% confidence intervals.
Long-term clinical adverse events, death due to cardiac
causes and MI of the target vessel were compared by Kaplan-
Meier survival curves, and the corresponding p value was
obtained from the log-rank test. Cumulative distribution
curves of MLD before stenting, immediately after stenting and
at follow-up were expressed as a function of CRP tertiles. For
graphical reasons, the two upper tertiles were combined and
compared with the lowest tertile of CRP values. Statistical
significance was assumed at p , 0.05.
Abbreviations and Acronyms
CRP 5 C-reactive protein
MI 5 myocardial infarction
MLD 5 minimal luminal diameter
PTCA 5 percutaneous transluminal coronary angioplasty
RR 5 relative risk
TVR 5 target vessel revascularization
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RESULTS
Baseline characteristics. The baseline clinical and proce-
dural characteristics of the study population are summarized
in Tables 1 and 2. Patients were grouped into tertiles
according to the CRP values. Elevated CRP levels were
defined as those in the two upper tertiles ($0.5 mg/dl). The
range of CRP values was 0.0 to 8.0 mg/dl.
Clinical parameters did not differ between the three
tertiles of CRP, with the exception that significantly more
patients with elevated levels of CRP ($0.5 mg/dl) presented
Table 1. Baseline Clinical Characteristics of the Study Population (n 5 276)
CRP < 0.5
(n 5 92)
CRP 0.5–1.4
(n 5 92)
CRP > 1.4
(n 5 92)
p
Value
Characteristics
Age 61 6 12 62 6 9 62 6 10 0.6
Women 17 (18.5%) 15 (16.3%) 24 (26.1%) 0.2
Mean LVEF (%) 53 6 10 52 6 12 50 6 11 0.7
Acute coronary syndrome 39 (42.3%) 44 (47.8%) 58 (63%) 0.02
Unstable angina 22 (23.9%) 32 (35.6%) 20 (21.7%) 0.08
Acute MI 17 (18.4%) 12 (13%) 38 (41.3%) 0.001
Risk factors
Current smoking 20 (21.7%) 22 (23.9%) 27 (29.3%) 0.7
Diabetes 12 (13%) 32 (34.8%) 18 (19.6%) 0.003
Hypertension 59 (64.1%) 45 (48.9%) 46 (50%) 0.1
Hypercholesterolemia 60 (65.2%) 60 (65.2%) 49 (53.3%) 0.2
Clinical
Previous MI 30 (32.6%) 38 (41.3%) 31 (33.7%) 0.5
Previous CABG 17 (18.5%) 13 (14.1%) 11 (12%) 0.4
Extent of disease
One-vessel 28 (30.4%) 29 (31.5%) 22 (24%) 0.6
Two-vessel 25 (27.2%) 26 (28.3%) 42 (45.7%) 0.01
Three-vessel 39 (42.4%) 37 (40.2%) 28 (30.4%) 0.15
CRP levels
CRP (mg/dl) 0.17 6 0.14 0.76 6 0.27 2.9 6 1.4 ,0.001
CABG 5 coronary artery bypass grafting; CRP 5 C-reactive protein; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction.
Table 2. Baseline Angiographic and Procedural Characteristics
CRP < 0.5
(n 5 92)
CRP 0.5–1.4
(n 5 92)
CRP > 1.4
(n 5 92)
p
Value
Characteristic
ACC/AHA lesion type
A 0 (0%) 0 (0%) 0 (0%) 1.0
B1 7 (7.6%) 8 (8.7%) 4 (4.3%) 0.09
B2 66 (71.7%) 66 (71.7%) 66 (71.7%) 0.8
C 19 (20.6%) 18 (19.6%) 22 (23.9%) 0.8
Vessel
LAD 48 (52.2%) 38 (41.3%) 37 (40.2%) 0.2
LCX 10 (10.9%) 16 (17.4%) 11 (12%) 0.4
RCA 28 (30.4%) 30 (32.6%) 39 (42.4%) 0.2
Vein graft 6 (6.5%) 8 (8.7%) 5 (5.4%) 0.6
Stent indication
Dissection 27 (29.3%) 28 (30.4%) 26 (28.3%) 0.9
Restenotic lesion 16 (17.4%) 14 (15.2%) 12 (13%) 0.4
Procedural
Lesion length (mm) 11 6 5 13 6 6 13 6 6 0.3
Max inflation pressure (atm) 13.8 6 1.7 14 6 1.5 13.8 6 1.7 0.5
Balloon/vessel ratio 1.05 6 0.1 1.03 6 0.1 1.05 6 0.1 0.2
Stent length (mm) 22 6 13 22 6 12 22 6 10 0.7
Stents/lesion 1.5 6 0.9 1.6 6 1 1.6 6 1 0.6
TIMI flow grade 3 91 (98.9%) 88 (95.7%) 91 (98.9%) 0.3
Residual dissections 12 (13%) 10 (10.9%) 4 (4.3%) 0.1
Residual stenosis $30% (stent) 7 (7.6%) 8 (8.7%) 5 (5.4%) 0.7
ACC/AHA 5 American College of Cardiology-American Heart Association; CRP 5 C-reactive protein; LAD 5 left anterior
descending coronary artery; LCX 5 left circumflex artery; RCA 5 right coronary artery; TIMI 5 Thrombolysis Myocardial
Infarction.
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with an acute coronary syndrome (defined as unstable
angina Braunwald class IIIB or acute MI, p 5 0.02). In
addition, more patients with CRP levels in tertiles II and III
were diabetic. The quantitative angiographic data at base-
line and immediately after coronary stent implantation are
summarized in Table 3. Angiographic parameters were
identical in all three groups.
Angiographic follow-up. Table 4 summarizes the quanti-
tative angiographic data obtained at follow-up angiography.
Patients with elevated CRP levels had significantly higher
restenosis rates. When the categorical criterion of $50%
diameter stenosis at follow-up was used to assess restenosis
development, the difference between the three groups was
highly significant (p , 0.005), with a restenosis rate of 19%
in the lowest tertile compared with 36.7% and 45.1% in the
upper tertiles, respectively. Figure 1, illustrating the cumu-
lative frequency distribution curves of the MLD, demon-
strates that late lumen loss was significantly greater in the
patients with elevated CRP levels (two upper tertiles
$0.5 mg/dl) compared with patients in the lowest tertile
(,0.5 mg/dl) as indicated by a leftward shift of the
cumulative frequency distribution curve at follow-up an-
giography (Table 5).
Clinical follow-up. Table 5 shows the major adverse
events during the one- and six-month follow-up period. To
account for local lesion-related outcomes, only MIs in the
territory of the target vessel, TVR and death due to cardiac
causes were included in the end point analysis. A primary
end point event occurred in 24 (26%) patients of the lowest
tertile, 42 (45.6%) patients of the middle tertile and in 38
(41.3%) patients of the highest CRP-tertile, p 5 0.01.
Thirteen early adverse events were observed within 30 days
after stent implantation. No event (MI or death) occurred in
the lowest tertile of CRP (,0.5 mg/dl). Importantly,
subacute stent thrombosis occurred exclusively in patients
with elevated CRP levels (upper tertiles). Six-month clinical
follow-up was completed in all patients. At six months,
MI or cardiac death occurred only in patients with pre-
procedural CRP levels $0.5 mg/dl (p 5 0.01). None of
the patients died of noncardiac causes. In addition, Figure
2 illustrates that survival free of MI and TVR was signifi-
cantly worse in patients with elevated preprocedural CRP
levels.
Multivariate analysis. RESTENOSIS. Logistic regression
analysis (Tables 6 and 7), including the classical previously
described predictors of restenosis after coronary stent im-
plantation, demonstrated that elevated preprocedural CRP
levels are independently associated with increased restenosis
rates (p 5 0.006) in addition to MLD immediately after
stent implantation (p 5 0.04) and the number of stents
implanted (p 5 0.02), whereas reference segment diameter
(p 5 0.6), diabetes (p 5 0.3) and total serum cholesterol
levels (p 5 0.3) did not independently predict subsequent
restenosis development. Interestingly, the presence of an
acute coronary syndrome that correlated with elevated CRP
levels was not an independent predictor for subsequent
recurrence rates (p 5 0.9). Thus, independent of classical
clinical and procedural risk factors, elevated preprocedural
CRP serum levels are associated with an increased risk for
in-stent restenosis, irrespective of the presence of an acute
coronary syndrome before stenting (RR 3.6 [1.7 to 7.7],
tertile III vs. I, p , 0.001).
CLINICAL EVENTS. Tertiles of CRP levels were also inde-
pendently associated with a higher risk of adverse coronary
events including MI, cardiac death and TVR (RR 5 2.0
Table 3. Baseline Quantitative Angiographic Analysis
Characteristics
CRP < 0.5
(n 5 92)
CRP 0.5–1.4
(n 5 92)
CRP > 1.4
(n 5 92)
p
Value
Quantitative analysis
Reference diameter (mm) 2.97 6 0.6 3.0 6 0.5 2.97 6 0.5 0.5
Minimal lumen diameter (mm) 0.81 6 0.6 0.78 6 0.5 0.7 6 0.6 0.5
Percent stenosis 74.4 6 17 74.8 6 16 79.1 6 17 0.2
Post-stent
Reference diameter (mm) 3.0 6 0.5 3.1 6 0.6 3.0 6 0.5 0.6
Minimal lumen diameter (mm) 2.66 6 0.6 2.65 6 0.6 2.60 6 0.5 0.9
Percent stenosis 14.3 6 11.6 15.4 6 11 15.2 6 11 0.5
Acute gain (mm) 1.9 6 0.6 2.0 6 0.7 1.9 6 0.7 0.4
CRP 5 C-reactive protein.
Table 4. Follow-up Quantitative Angiographic Analysis
Follow-up
(n 5 229)
CRP < 0.5
(n 5 79)
CRP 0.5–1.4
(n 5 79)
CRP > 1.4
(n 5 71)
p
Value
Reference diameter (mm) 3.0 6 0.5 3.0 6 0.5 3.0 6 0.5 0.5
Minimal lumen diameter (mm) 1.95 6 0.8 1.71 6 0.8 1.67 6 0.9 0.1*
Percent stenosis 35 6 21 45 6 22 45 6 27 0.01
Late loss (mm) 0.66 6 0.7 1.03 6 0.8 0.97 6 0.8 0.02
Restenosis rate 15 (19%) 29 (36.7%) 32 (45.1%) 0.002
*p 5 0.05, Tertile 1 vs. Tertile 3.
CRP 5 C-reactive protein.
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[1.1 to 3.5], tertile I vs. II and III, p 5 0.01) in addition to
the MLD after stent (p 5 0.04). Since, in patients with
acute MI, circulating CRP levels might be elevated due to
myocardial necrosis, we repeated the analysis after excluding
patients with acute MI. However, an almost identical RR of
2.3 ([1.2 to 4.2], tertile I vs. II and III, p 5 0.006) was
observed for elevated CRP levels in this subset of 208
patients, thus excluding a potential confounding effect of
MI patients being more frequently distributed in the upper
tertiles of CRP levels.
In contrast, stent length, reference vessel size, hypercho-
lesterolemia, diabetes or acute coronary syndromes did not
appear to be of predictive value for subsequent adverse
events.
DISCUSSION
The results of this study demonstrate that elevated prepro-
cedural CRP levels are associated with enhanced restenosis
development after coronary stent implantation. Most im-
portantly, the increased restenosis rate associated with
elevated CRP levels is accompanied by a worse event-free
survival.
The results of this study extend previous observations,
demonstrating the predictive value of measuring CRP levels
for cardiovascular events after coronary interventions. In
patients undergoing conventional single-vessel balloon an-
gioplasty, preprocedural CRP levels have been shown to be
a powerful predictor of early and late clinical outcome (11).
Figure 1. Cumulative frequency distribution curves of the MLD for tertiles of CRP levels pre-, post-stent implantation and at six-month follow-up
angiography. For graphical reasons, the two upper tertiles ($0.5 mg/dl) were combined (dotted line with circles) and compared with the lowest tertile
(,0.5 mg/dl). CRP 5 C-reactive protein; MLD 5 minimal lumen diameter.
Table 5. Major Adverse Clinical Events at One-Month and Six-Month Clinical Follow-up
One-Month Follow-up
CRP < 0.5
(n 5 92)
CRP 0.5–1.4
(n 5 92)
CRP > 1.4
(n 5 92)
p
Value
Primary combined end point
(target vessel MI, death,
TVR)
24 (26%) 42 (45.6%) 38 (41.3%) 0.02*
Subacute stent thrombosis 0 (0%) 3 (3.3%) 4 (4.3%) 0.1
Myocardial infarction
(target vessel 30 days)
0 (0%) 2 (2.2%) 2 (2.2%) 0.3
Death (30 days) 0 (0%) 1 (1.1%) 1 (1.1%) 0.6
>1–6 Month Follow-up
Myocardial infarction
(target vessel 6 month)
0 (0%) 3 (3.3%) 5 (5.4%) 0.08
Myocardial infarction
(nontarget vessel 6 month)
0 (0%) 1 (1.1%) 2 (2.2%) 0.4
Death 6 month 0 (0%) 3 (3.3%) 4 (4.3%) 0.15
Target vessel
revascularization
24 (26%) 34 (36.9%) 29 (31.5%) 0.2
Cardiac events (Target vessel
MI, death)
0 (0%) 8 (8.7%) 9 (9.8%) 0.01
*log-rank (Kaplan-Meier) p 5 0.01.
CRP 5 C-reactive protein; MI 5 myocardial infarction; TVR 5 target vessel revascularization.
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In addition, in patients with stable angina and one-vessel
disease, normalization of CRP plasma levels after coronary
stenting identified patients who do not develop cardiovas-
cular events (10). In line with a previous study in patients
undergoing balloon angioplasty (11), in our population, no
adverse coronary event such as MI or death within six
months occurred in the subset of patients with CRP levels
in the lowest tertile. Thus, preprocedural measurement of
CRP levels might allow stratification of patients with
respect to the individual risk for both early and late
complications after coronary stent implantation.
Previous studies revealed that, in patients with unstable
angina undergoing PTCA, increased baseline levels of
acute-phase proteins are a marker for the hyperresponsive-
ness of the inflammatory system to nonspecific stimuli (9).
In-hospital complications after coronary stent implanta-
tion are mainly due to subacute stent thrombosis or occlu-
sions caused by procedural parameters such as residual
dissections (16,17). Indeed, in our study, all early compli-
cations after stent implantation within 30 days were events
due to subacute thrombus formation at the stented site.
Activation of inflammatory cells and cytokines can aggra-
vate local thrombotic complications by increasing procoagu-
lant or platelet activity or promoting thrombin generation
(18–20). The finding of this study, that subacute stent
thrombosis was exclusively observed in patients with ele-
vated CRP levels, suggests an important role for low-grade
systemic inflammation to amplify local thrombotic compli-
Figure 2. Long-term clinical adverse events (death due to cardiac causes, myocardial infarction of the target vessel and target vessel revascularization) within
tertiles of CRP levels are compared by Kaplan-Meier survival curves, and the corresponding p value was obtained from the log-rank test. CRP 5 C-reactive
protein.
Table 6. Logistic Regression Analysis for Stent Restenosis
Variables
Multivariate Analysis
Relative Risk
(95% CI)
p
Value
CRP (tertiles) 0.006
III vs. I 3.6 (1.7–7.7) ,0.001
II vs. I 2.7 (1.3–5.5) 0.005
II 1 III vs. I 3.1 (1.6–5.9) ,0.001
MLD (Stent) 0.04
Stent length (mm) 0.02
Reference diameter (mm) 0.6
Diabetes 0.3
Hypercholesterolemia 0.3
Acute coronary syndrome 0.9
CI 5 confidence interval; CRP 5 C-reactive protein; MLD 5 minimal lumen
diameter.
Table 7. Logistic Regression Analysis for Clinical Outcome
(MI, Death, TVR)
Variables
Multivariate Analysis
Relative Risk
(95% CI)
p
Value
CRP (tertiles) 0.01
III vs. I 1.9 (1.1–3.5) 0.04
II vs. I 2.2 (1.2–4.0) 0.01
II 1 III vs. I 2.0 (1.1–3.5) 0.01
MLD (stent) 0.04
Stent length (mm) 0.1
Reference diameter (mm) 0.5
Diabetes 0.7
Hypercholesterolemia 0.1
Acute coronary syndrome 0.5
CI 5 confidence interval; CRP 5 C-reactive protein; MLD 5 minimal lumen
diameter; MI 5 myocardial infarction; TVR 5 target vessel revascularization.
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cations in patients undergoing coronary stent implantation
(21).
Although the presence of an acute coronary syndrome
correlated with elevated baseline CRP levels, by multivariate
analysis it was not an independent predictor for subsequent
clinical and angiographic outcome in our patient population
consisting of a consecutive series of patients with various
clinical conditions, including stable and unstable angina as
well as MI. Likewise, diabetes did not appear to be an
independent predictor, once preprocedural CRP levels were
included in the analysis. Thus, since elevated CRP levels
cluster in patients with diabetes (22), it is tempting to
speculate that the systemic inflammatory activity as mea-
sured by CRP serum levels might be more informative than
classical risk factors with respect to predicting the clinical
and angiographic outcome after coronary stent implanta-
tion.
Experimental and clinical studies demonstrated that a
systemic inflammatory reaction plays a pivotal role for
neointima formation within stents in addition to the local
vessel wall injury with the subsequent release of chemotactic
and growth factors (9,23). Stent implantation has been
shown to provide superior late results compared with
conventional balloon angioplasty (24,25), which has been
attributed to the elimination of chronic vessel wall shrinkage
even at the expense of increased neointimal proliferation.
Thus, coronary stent implantation provides an ideal scenario
to assess the role of inflammation in atherosclerotic disease
progression that is primarily determined by neointimal
hyperplasia and not affected by a chronic shrinking process
after conventional balloon angioplasty (12). In addition,
stenting provides a more homogenous lesion geometry by
covering plaque fractures and reducing exposure of athero-
matous material, which might locally modify the biological
response of a dilated lesion. However, the concordant
finding that preprocedural CRP levels predict clinical and
angiographic outcome both after balloon dilation (11) and
after stent implantation suggests that—in both condi-
tions—the preprocedural activation of inflammatory cells
(26) may play a major role in the modulation of the
vessel-wall response to injury.
Study limitations. In this study, CRP values were mea-
sured by a turbidimetric method and not with the recently
recommended latex-enhanced high-sensitive CRP assay.
However, comparison of the two assays in our institution
not only revealed a very close correlation but, more impor-
tantly, demonstrated that CRP levels $0.5 mg/dl (upper
limit of the lowest tertile) can be reliably detected using the
turbidimetric method (data not shown). Although we
achieved a high repeat angiography rate of 85.7%, we cannot
fully exclude a potential bias related to incomplete angio-
graphic follow-up. However, such bias is unlikely to be
of relevance since the prospective design of the study
allowed to assure that the patients without angiographic
follow-up did not differ with respect to CRP distribution
and clinical outcome.
Conclusions. Our study shows that low-grade inflamma-
tion measured by elevated preprocedural CRP-levels is an
important and independent predictor of acute and six-
month adverse outcome after coronary stent implantation,
suggesting that a systemic inflammatory activity is associ-
ated with thrombotic and proliferative responses within
successfully implanted stents.
Measurement of CRP levels could provide a rationale for
risk stratification before coronary intervention and, thus,
may offer a useful tool to target aggressive antiaggregatory or
anti-inflammatory therapy to patients that are exposed to
the highest risk for ischemic complications or restenosis
development after coronary stent implantation.
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